Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia

Volumn 30, Issue 5, 2016, Pages 1044-1054

  Hochhaus, A ^a   Saglio, G ^b   Hughes, T P ^c   Larson, R A ^d   Kim, D W ^e   Issaragrisil, S ^f   Le Coutre, P D ^g   Etienne, G ^h   Dorlhiac Llacer, P E ⁱ   Clark, R E ^j   Flinn, I W ^k   Nakamae, H ^l   Donohue, B ^m   Deng, W ^m   Dalal, D ^m   Menssen, H D ^m   Kantarjian, H M ⁿ  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF CHICAGO   (United States)

^e The Catholic University of Korea   (South Korea)

^f MAHIDOL UNIVERSITY   (Thailand)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h INSTITUT BERGONIÉ   (France)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^k SARAH CANNON RESEARCH INSTITUTE   (United States)

^l Osaka Prefecture University   (Japan)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANAGRELIDE; ANTIDIABETIC AGENT; BCR ABL PROTEIN; BILIRUBIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; IMATINIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NILOTINIB; TRIACYLGLYCEROL LIPASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; GLUCOSE BLOOD LEVEL; PYRIMIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CONVULSION; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DISORDERS OF CHOLESTEROL METABOLISM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EVENT FREE SURVIVAL; FAINTNESS; FATIGUE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FLUTTER; HEART VENTRICLE TACHYCARDIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIVER TOXICITY; LONG TERM SURVIVAL; LUNG EDEMA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MORTALITY RATE; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PULMONARY HYPERTENSION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETINA VEIN OCCLUSION; RHINOPHARYNGITIS; SECOND CANCER; SIDE EFFECT; SUDDEN CARDIAC DEATH; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; VOMITING; BLOOD; COMPARATIVE STUDY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; METABOLISM; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

BLOOD GLUCOSE; CHOLESTEROL; FOLLOW-UP STUDIES; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; PYRIMIDINES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84959482245     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.5     Document Type: Article

References (33)

1. Tasigna (nilotinib) [package insert]. Novartis Pharmaceuticals Corporation: East Hanover, NJ, USA, 2015.
2. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
3. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
4. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203.
5. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-1360.
6. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. V1 2016.
8. Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121: 3703-3708.
9. Gepner AD, Korcarz CE, Colangelo LA, Hom EK, Tattersall MC, Astor BC et al. Longitudinal effects of a decade of aging on carotid artery stiffness: the multiethnic study of atherosclerosis. Stroke 2014; 45: 48-53.
10. Kim MS, Kang SJ, Lee CW, Han S, Park DW, Lee SW et al. Prevalence of coronary atherosclerosis in asymptomatic healthy subjects: an intravascular ultrasound study of donor hearts. J Atheroscler Thromb 2013; 20: 465-471.
11. Wilke T, Mueller S, Groth A, Fuchs A, Seitz L, Kienhöfer J et al. Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229, 042 patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2015; 14: 14.
12. Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica 2014; 99: 1204-1211.
13. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009; 94: 1362-1367.
14. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
15. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
16. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
17. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45.
18. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: S11-S61.
19. Etienne G, Dulucq S, Nicolini FE, Morrisset S, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy. Haematologica 2014; 99: 458-464.
20. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014; 32: 415-423.
21. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res 2014; 20: 310-322.
22. Hochhaus A, Rosti G, Cross NCP, Steegmann JL, le Coutre P, Ossenkoppele G et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016; 30: 57-64.
23. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238.
24. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121: 4867-4874.
25. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-2102.
26. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310-1315.
27. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316-1321.
28. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947-953.
29. Breccia M, Molica M, Zacheo I, Serrao A, Alimena G. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol 2015; 94: 393-397.
30. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117: e75-e87.
31. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494-500.
32. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
33. Iclusig (ponatinib) [package insert]. ARIAD Pharmaceuticals: Cambridge, MA, USA, 2014.